The invention relates to the compounds of the formula
and pharmaceutically acceptable salts thereof, in which :
R is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid ;
R1 is a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical and a cycloaliphatic hydrocarbon radical ;
X1 and X3, independently of one another, are oxygen (-O-) or sulphur (-S-) ; and
X2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical ;
wherein the phenyl rings of formula I may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ;
wherein aryl in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ; and wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical. The compounds are useful as selective LTB-4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB-4 receptor antagonism.
本发明涉及如下式的化合物
及其药学上可接受的盐,其中:
R 是氢或酰基,酰基来源于有机
碳酸、有机
羧酸、
磺酸或
氨基甲酸;
R1 是选自脂肪烃基、脂肪烃基和环脂肪烃基的取代基;
X1 和 X3 互不相关,分别为氧 (-O-) 或
硫 (-S-);以及
X2 是二价脂肪族烃基,可被芳香族基打断;
其中式 I 的苯基环可相互独立地进一步被一个或多个取代基取代,这些取代基可选 自卤素、三
氟甲基、脂肪族烃基、羟基和被脂肪族、脂肪族或环脂肪族醇醚化或被脂 肪族或
脂肪族羧酸酯化的羟基;
其中,上述定义中的芳基可彼此独立地进一步被一个或多个取代基取代,这些取代基选自卤素、三
氟甲基、脂肪族烃基、羟基和被脂肪族、脂肪族或环脂肪族醇醚化或被脂肪族或
脂肪族羧酸酯化的羟基;其中,环脂肪族烃基可被脂肪族基取代。这些化合物可作为选择性LTB-4受体拮抗剂,用于治疗哺乳动物体内对LTB-4受体拮抗剂有反应的病症或综合征。